BioSpace News Archive

Partnership aims to deliver the most comprehensive, cost effective and high throughput cancer sequencing and interpretation service in Europe, to enable improved cancer patient management, treatment, and monitoring

The FUSE Study is designed to demonstrate the superiority of Circumferential Cervical Fusion over traditional ACDF in patients at high risk for nonunion or revisions.

Results show a pre-treatment with a micro dose (150 µg) of Gvoke RTU Micro significantly prevented Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a real-world setting with or without adjustment to insulin

Additional Abstracts on Health Economics and Outcomes Research and Other Data Accepted as Poster Presentations

Immunic, Inc. announced dosing of the first patients in its phase 2, CALVID-1 clinical trial of IMU-838, the company’s selective oral DHODH inhibitor, in coronavirus disease 2019, at several sites in different European countries.

Catalyst Biosciences, Inc., announced final efficacy and safety data from its Phase 2b trial of DalcA, a next-generation subcutaneously administered Factor IX therapy being developed for the treatment of Hemophilia B.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that its abstract has been accepted for oral virtual presentation at the 3rd Annual Next Gen Immuno-Oncology Congress, which takes place from 25-26 June 2020.

Solasia Pharma K.K., a specialty pharmaceutical company based in Asia, announced the positive results from the pivotal Phase 2 study with SP-02 for relapsed or refractory peripheral T-cell lymphoma in Asia.

Therapeutics Solutions International, Inc., issues the following cautionary notice to the shareholders and public at large.

These Data Demonstrate Breadth of Takeda’s Portfolio and Pipeline with Three Hematology Presentations at the Virtual Summit